Novo Nordisk stock slides
Digest more
The MarketWatch News Department was not involved in the creation of this content. The Novo Nordisk Foundation proposes new candidates for election as members of the Board of Directors of Novo Nordisk A/S COPENHAGEN, Denmark, Oct. 21, 2025 /PRNewswire ...
Newly-elected chairman of Wegovy-maker Novo Nordisk , Lars Rebien Sorensen, said on Friday he plans to enhance the board's pharmaceutical and over-the-counter experience following a board overhaul at an extraordinary shareholder meeting.
Novo Nordisk experienced a major board reshuffle at a recent shareholder meeting, led by the Novo Nordisk Foundation. This power transition follows governance disagreements and leadership changes, as the company struggles with profit warnings,
Novo Holdings A/S, a vehicle for the Novo Nordisk Foundation, is set to exit its remaining position in medical technology firm Convatec Group Plc with a 7.8% stake sale.
The Novo Foundation, through its subsidiary Novo Holdings, owns 25% of the shares and 70% of the votes in Novo Nordisk, making the election of its designees a likely formality when investors gather for the Nov. 14 meeting. The board changes come amid a ...
The Wall Street Journal on MSN
Novo Nordisk Says Mikael Dolsten Won't Seek Election to Board at Friday's Meeting
Shareholders will vote Friday on the appointment of Lars Rebien Sorensen as chair, Cees de Jong as vice chair, and Britt Meelby Jensen and Stephan Engels as board members. Current board members Kasim Kutay, Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bojer Jensen and Thomas Rantzau remain in their positions.
Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and consumer-market leadership in the GLP-1 era without deeper American commercial expertise.
Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera , as investors had viewed its offer as too complex.
The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it.
Feedback